ImmunoVaccine Technologies Inc. to Acquire Immunotope Inc.
ImmunoVaccine Technologies Inc. (IVT) has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.
The acquisition will bring together IVT's signature VacciMax(R) platform with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform, allowing the new private company to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines.
The combined clinical-stage company will continue to support Immunotope's ongoing Phase 1 immunotherapeutic vaccine clinical trial in ovarian and breast cancer patients at Duke University Comprehensive Cancer Center.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Helix announces election of new board member
Miroslav Radman wins the 2011 FEMS-Lwoff Award.
HIV-derived antibacterial shows promise against drug-resistant bacteria
Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan
Zelluna Immunotherapy appoints Miguel Forte as Chief Executive Officer - Appointment to drive Zelluna through next stage of international clinical-phase development
Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals
Sigma-Aldrich and Sangamo BioSciences Announce Alliance to Develop Zinc Finger-Based Laboratory Research Reagents
Cardio3 BioSciences Receives ISO-13485 Certification
Gene Logic Expands International Operations - Establishes Staff in UK and Germany - Forms Gene Logic K.K. to Serve Japanese Market

New way in which insulin interacts with its receptor discovered
Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced Dyskinesia in Parkinson's
